Another proposed class action filed on behalf of children born with Neonatal Abstinence Syndrome accuses a group of pharmaceutical companies and distributors of contributing to the 'opioid epidemic' that has swept across the state of Louisiana.
Three municipalities have sued a group of 11 pharmaceutical companies claiming towns and cities in Pennsylvania have suffered 'a public health and safety crisis' as a result of the defendants’ alleged misrepresentation of their opioid medications.
Another proposed class action filed on behalf of a minor child diagnosed with NAS has been added to the multidistrict litigation involving pharmaceutical companies’ and distributors’ alleged contributions to the country’s growing 'opioid epidemic.'
A growing number of lawsuits have been filed against a group of pharmaceutical companies and distributors over claims that the defendants have caused a national health crisis by deceptively marketing opioids for long-term use.
Another proposed class action has been filed against a group of 22 pharmaceutical companies and distributors over claims that the defendants’ deceptive marketing scheme and negligence have fueled the nation’s growing opioid crisis.
A group of 20 pharmaceutical companies and distributors has been named in a proposed class action lawsuit filed on behalf of a newborn baby who the suit claims suffers from neonatal abstinence syndrome (NAS) as a result of the defendants’ actions.
Three Mississippi hospitals claim the conduct of 19 pharma-industry heavyweights contributed greatly to the nation's opioid abuse epidemic.
Another proposed class action has been filed against various pharmaceutical companies and distributors, claiming the defendants’ deceptive marketing of opioid products has contributed to their widespread abuse.
A proposed class action has been filed against a group of pharmaceutical companies and distributors over claims that they deceptively marketed and sold opioids without fully disclosing their associated risks.